News
ALNY
256.45
-3.19%
-8.44
BPMC Q4 Earnings and Sales Miss Estimates, Shares Decline
NASDAQ · 22h ago
Alnylam Pharmaceuticals Price Target Cut to $300.00/Share From $310.00 by Scotiabank
Dow Jones · 23h ago
Alnylam Pharmaceuticals Is Maintained at Sector Outperform by Scotiabank
Dow Jones · 23h ago
ALNYLAM PHARMACEUTICALS INC <ALNY.O>: CANACCORD GENUITY RAISES TARGET PRICE TO $385 FROM $384
Reuters · 1d ago
Alnylam Pharmaceuticals Price Target Raised to $284.00/Share From $275.00 by Morgan Stanley
Dow Jones · 1d ago
Alnylam Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 1d ago
Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $284
Benzinga · 1d ago
ALNYLAM PHARMACEUTICALS INC <ALNY.O>: MORGAN STANLEY RAISES TARGET PRICE TO $284.00 FROM $275.00
Reuters · 1d ago
Alnylam price target lowered to $300 from $310 at Scotiabank
TipRanks · 1d ago
Morgan Stanley Reaffirms Their Hold Rating on Alnylam Pharma (ALNY)
TipRanks · 1d ago
Scotiabank Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
TipRanks · 1d ago
ALNYLAM PHARMACEUTICALS INC <ALNY.O>: RAYMOND JAMES RAISES TARGET PRICE TO $308 FROM $298
Reuters · 1d ago
Alnylam Pharma (ALNY) Gets a Buy from Barclays
TipRanks · 1d ago
Alnylam Pharmaceuticals Price Target Maintained With a $320.00/Share by Needham
Dow Jones · 1d ago
Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $320 Price Target
Benzinga · 1d ago
Alnylam Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations
Simply Wall St · 1d ago
Strong Buy Recommendation for Alnylam Pharma Amid Upcoming PDUFA Date and Promising Growth Prospects
TipRanks · 1d ago
Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y
Barchart · 1d ago
Alnylam Pharmaceuticals sees $1.6B to $1.725B TTR revenue in 2025 driven by AMVUTTRA expansion
Seeking Alpha · 1d ago
ALNYLAM PHARMACEUTICALS INC <ALNY.O>: SCOTIABANK CUTS TARGET PRICE TO $300 FROM $310
Reuters · 1d ago
More
Webull provides a variety of real-time ALNY stock news. You can receive the latest news about Alnylam Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ALNY
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. In addition, the Company develops Cemdisiran to treat complement-mediated diseases, Belcesiran for the treatment of alpha-1 liver disease, Elebsiran, Zilebesiran, ALN-APP, ALN-HSD, Fitusiran, and others.